Island Pharmaceuticals received FDA authorization to use existing Marburg virus natural history data to support its planned Galidesivir Animal Rule submission, potentially reducing the need for additional studies. The data will help establish disease progression and support the development of Galidesivir as a treatment for Marburg virus disease, building on preclinical studies showing survival benefits in non-human primates. The authorization is an important step toward Island’s FDA regulatory pathway for Galidesivir, which has also received FDA orphan-drug designation for Marburg post-exposure prophylaxis.
